Stockreport
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
The Zacks Consensus Estimate for fourth-quarter sales and earnings is pegged at $24.14 billion and $2.50 per share, respectively. The Zacks Consensus Estimate for 2025 earnings has declined from $10.87 per share to $10.83 per share, while that for 2026 has declined from $11.48 per share to $11.46 per share over the past 60 days. Image Source: Zacks Investment Research The healthcare bellwether's performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 3.75%, on average. In the last reported quarter, the company delivered an earnings surprise of 1.08%. Image Source: Zacks Investment Research J&J has an Earnings ESP of -1.36% and a Zacks Rank #3 (Hold). You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Stron
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access[Business Wire]
- Amgen (NASDAQ:AMGN) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $335.00 price target on the stock.[MarketBeat]
- Kaléo Strengthens Leadership Team to Advance Drug Delivery and Autoinjector Innovation [Yahoo! Finance][Yahoo! Finance]
- Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? [Yahoo! Finance][Yahoo! Finance]
- Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 80% of the company [Yahoo! Finance][Yahoo! Finance]
- More
AMGN
SEC Filings
SEC Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website
- More